Antitumor effect of an anti-human mullerian inhibiting substance type II receptor antibody in a nude mouse model for granulosa cell tumors: a new targeted therapy for ovarian cancer

被引：0
|
作者：
Kersual, N. [1 ]
Garambois, V [1 ]
Salhi, I [1 ]
Larbouret, C. [1 ]
Bibeau, F. [2 ]
Cambon-Roques, S. [2 ]
Mollevi, C. [2 ]
Colombo, P. E. [2 ]
Theillet, C. [1 ]
Pelegrin, A. [1 ]
Teulon, I [1 ,3 ]
机构：
[1] IRCM, F-34298 Montpellier, France
[2] Univ Montpellier 1, INSERM, U896, F-34298 Montpellier, France
[3] CRLC Val DAurelle Paul Lamarque, F-34298 Montpellier, France
来源：
BULLETIN DU CANCER | 2008年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S36 / S36
页数：1
相关论文
共 14 条
  • [1] Anti-tumor effect of an anti-human Mullerian Inhibiting Substance type II receptor antibody in a nude mouse model for granulosa cell tumors: a new targeted therapy for ovarian cancer
    Kersual, N.
    Garambois, V.
    Salhi, I.
    Larbouret, C.
    Bibeau, F.
    Mollevi, C.
    Chardes, T.
    Pelegrin, A.
    Teulon, I.
    EJC SUPPLEMENTS, 2008, 6 (12): : 163 - 163
  • [2] Anti-tumor effect of an anti-human mullerian inhibiting substance type II receptor antibody in mouse models for ovarian cancer: towards a new targeted therapy
    Kersual, Nathalie A.
    Garambois, Veronique
    Salhi, Imed
    Chardes, Thierry
    Colombo, Pierre Emmanuel
    Bascoul-Mollevi, Caroline
    Cambon-Roques, Sylvie
    Bibeau, Frederic
    Pouget, Jean Pierre
    Behrens, Christian
    Gaucher, Christine
    Urbain, Remy
    Prose, Jean Frangois
    Pelegrin, Andre
    Navarro-Teulon, Isabelle
    CANCER RESEARCH, 2011, 71
  • [3] Towards a new targeted therapy for ovarian cancer : Development of an anti-human mullerian inhibiting substance type II receptor humanized antibody
    Jacquet, Alexandra
    Kersual, Nathalie
    Garambois, Veronique
    Colombo, Pierre-Emmanuel
    Goncalvez, Rui-Bras
    Theillet, Charles
    Gaucher, Christine
    Fournier, Nathalie
    De Romeuf, Christophe
    Prost, Jean-Francois
    Urbain, Remi
    Pelegrin, Andre
    Teulon-Navarro, Isabelle
    CANCER RESEARCH, 2011, 71
  • [4] 3C23K: an anti-human Mullerian inhibiting substance type II receptor humanized monoclonal antibody for ovarian cancer targeted therapy
    Jacquet, Alexandra
    Kersual, Nathalie
    Garambois, Veronique
    Fontayne, Alexandre
    Pujols, Fanny
    Fournier, Nathalie
    Pugniere, Martine
    Chavanieu, Alain
    de Romeuf, Christophe
    Prost, Jean-Francois
    Urbain, Remi
    Pelegrin, Andre
    Gaucher, Christine
    Teulon-Navarro, Isabelle
    CANCER RESEARCH, 2012, 72
  • [5] Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer
    Yuan, Qing-an
    Simmons, Heidi H.
    Robinson, Matthew K.
    Russeva, Maria
    Marasco, Wayne A.
    Adams, Gregory P.
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (08) : 2096 - 2105
  • [6] High level prokaryotic expression of anti-Mullerian inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging
    Ortega, Celine
    Herbet, Amaury
    Richard, Sophie
    Kersual, Nathalie
    Costa, Narciso
    Pelegrin, Andre
    Ducancel, Frederic
    Couraud, Jean-Yves
    Navarro-Teulon, Isabelle
    Boquet, Didier
    JOURNAL OF IMMUNOLOGICAL METHODS, 2013, 387 (1-2) : 11 - 20
  • [7] Radiolabeled Antibodies Against Mullerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer
    Deshayes, Emmanuel
    Ladjohounlou, Riad
    Le Fur, Pierre
    Pichard, Alexandre
    Lozza, Catherine
    Boudousq, Vincent
    Sevestre, Samuel
    Jarlier, Marta
    Kashani, Roxana
    Koch, Joanna
    Sosabowski, Jane
    Foster, Julie
    Chouin, Nicolas
    Bruchertseifer, Frank
    Morgenstern, Alfred
    Kotzki, Pierre-Olivier
    Navarro-Teulon, Isabelle
    Pouget, Jean-Pierre
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (08) : 1234 - 1242
  • [8] Human ovarian cancer, cell lines, and primary ascites cells express the human mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS
    Masiakos, PT
    MacLaughlin, DT
    Maheswaran, S
    Teixeira, J
    Fuller, AF
    Shah, PC
    Kehas, DJ
    Kenneally, MK
    Dombkowski, DM
    Ha, TU
    Preffer, FI
    Donahoe, PK
    CLINICAL CANCER RESEARCH, 1999, 5 (11) : 3488 - 3499
  • [9] The human Mullerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer Validation using the mAb 12G4
    Kersual, Nathalie
    Garambois, Veronique
    Chardes, Thierry
    Pouget, Jean-Pierre
    Salhi, Imed
    Bascoul-Mollevi, Caroline
    Bibeau, Frederic
    Busson, Muriel
    Vie, Henri
    Clemenceau, Beatrice
    Behrens, Christian K.
    Estupina, Pauline
    Pelegrin, Andre
    Navarro-Teulon, Isabelle
    MABS, 2014, 6 (05) : 1314 - 1326
  • [10] Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo
    Pieretti-Vanmarcke, R
    Donahoe, PK
    Szotek, P
    Manganaro, T
    Lorenzen, MK
    Lorenzen, J
    Connolly, DC
    Halpern, EF
    MacLaughlin, DT
    CLINICAL CANCER RESEARCH, 2006, 12 (05) : 1593 - 1598
12